ALLMedicine™ Factor X Deficiency Center

May 3rd, 2022 - Hereditary factor X (FX) deficiency (FXD) is a rare autosomal recessive bleeding disorder. Plasma-derived FX (pdFX) is a high-purity FX concentrate approved in the United States and Europe for the treatment and prophylaxis of bleeding episodes and...

Mar 4th, 2022 - Factor X is synthesized in the liver, and vitamin K is required for its production. The reference range of factor X is 45-155% of normal.[1] Factor X levels are increased in pregnancy and in association with oral contraceptives. Defects in protein...

Mar 4th, 2022 - Reference Range Factor X is synthesized in the liver, and vitamin K is required for its production. The reference range of factor X is 45-155% of normal. [1] Next: Interpretation Factor X levels are increased in pregnancy and in association with o...

Feb 11th, 2022 - Factor X deficiency is a rare bleeding disorder that affects almost 1 : 1000 000 people worldwide. It derives from multiple mutational changes in the factor X gene (F10). The main objective of the present study was to determine a consistent correl...

Nov 12th, 2021 - The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor...

Nov 12th, 2021 - The primary objective is to collect additional surgical data on the clinical effectiveness of Coagadex, in a post-marketing environment, for peri-operative hemostatic cover during major surgery in patients with moderate or severe hereditary factor...

Dec 12th, 2014 - The main objective of the study is to assess the pharmacokinetics of FACTOR X after a single dose of 25IU/kg. The secondary objectives of the study are to assess efficacy and safety of FACTOR X in the treatment of bleeding episodes over at least 6...

Jul 20th, 2017 - Vials and a syringe BERLIN—Results of a phase 3 study suggest prophylaxis with plasma-derived factor X (pdFX, Coagadex®) prevents or reduces bleeding episodes in children with moderate to severe hereditary factor X deficiency (FXD). pdFX was well.

Feb 8th, 2016 - Drug vials and a syringe The European Medicines Agency (EMA) has recommended marketing authorization for Coagadex to treat hereditary factor X deficiency, a rare bleeding disorder. The active substance in Coagadex is coagulation factor X, a protei.

Oct 22nd, 2015 - Vials and a syringe The US Food and Drug Administration (FDA) has approved a factor X product derived from human plasma (Coagadex) to treat patients with hereditary factor X deficiency who are 12 years of age and older. Coagadex is approved for on.

Oct 21st, 2015 - The U. S.

Oct 21st, 2015 - The U. S.